Roundtable Discussion: Oral Therapies & the Future of Biologics, How Oral Peptides and Small Molecules Are Reshaping the Immunology Landscape
- How emerging biologic formats (nanobodies, bispecifics, multi-pathway antibodies change the logic of indication selection
- When crowded indications like psoriasis or AD make sense as platform-validation settings rather than commercial endpoint
- Trade-offs between rare diseases and common diseases as first-in-human or firstproof-of-concept opportunities
- What level and type of early data regulators and pharma partners actually need to believe in a platform
- Balancing scientific elegance, capital efficiency, CMC risk, and partnering attractiveness in early development decisions